Ara Metjian, MD
Hematology & Oncology · Aurora, CONPI 1679635502
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,420 of the $88,894 with a category attached, or 79.2%. 18 manufacturers reported payments, led by Sanofi at 38.7% of the total. 2025 is the largest year on record at $33,476, 2.4 times the $14,065 reported in 2019.
Across 86 payments — averaging $1033.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$34K
- Omeros Corporation$17K
- Sanofi US Services Inc.$15K
- Novartis$6K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Genentech USA, Inc.$4K
- plus $8K from 12 others
Across 99 payments — averaging $6151.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$197K
- Takeda Pharmaceuticals U.S.A., Inc.$105K
- Janssen Research & Development, LLC$101K
- Ablynx NV$81K
- Sanofi$53K
- Genentech, Inc.$33K
- plus $38K from 4 others
What the payments were for
- Consulting fees$70,42079%
- Speaking & faculty fees$8,72710%
- Travel & lodging$5,4046%
- Food & beverage$4,3435%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 27 | $34,412 |
| Omeros Corporation | 2 | $17,010 |
| Sanofi US Services Inc. | 1 | $14,507 |
| Novartis | 8 | $5,537 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $4,969 |
| Genentech USA, Inc. | 4 | $4,200 |
| Janssen Scientific Affairs, LLC | 2 | $3,477 |
| Argenx US, Inc. | 12 | $3,057 |
| AstraZeneca | 5 | $499 |
| Tersera Therapeutics LLC | 1 | $408 |
| Alnylam Pharmaceuticals Inc. | 3 | $277 |
| Karyopharm Therapeutics Inc. | 1 | $131 |
| Apellis Pharmaceuticals, Inc. | 1 | $119 |
| Dova Pharmaceuticals | 1 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $74 |
| Bayer | 1 | $49 |
| Novo Nordisk | 1 | $48 |
| Recordati_rare_diseases_inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,894 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $27,788 |
| XareltoRivaroxaban | 20 | $19,579 |
| Hydroxyurea | 13 | $474 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ryan WeightAurora$65K
- Breelyn WilkyAurora$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.